Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure

Background and aims Oxaliplatin (OX) has been described as a potential etiologic agent for porto-sinusoidal vascular disorder (PSVD). Our aim was to describe the natural history of PSVD due to OX in colon cancer (CRC) and identify risk factors for its development. Methods We made a multicenter retro...

ver descrição completa

Detalhes bibliográficos
Autores: Puente, A., Fortea, José Ignacio, Pozo, C. del, Serrano, M., Alonso Peña, M., Giráldez, A., Rodríguez Seguel, Elisa del Pilar, Crespo, J.
Tipo de documento: artigo
Estado:Versión aceptada para publicación
Data de publicação:2024
País:España
Recursos:Universidad de Sevilla (US)
Repositório:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/167505
Acesso em linha:https://hdl.handle.net/11441/167505
https://doi.org/10.1016/j.dld.2024.04.010
Access Level:Acceso aberto
Palavra-chave:Oxaliplatin
Idiopathic portal hypertension
Porto-sinusoidal vascular disorder
Portal hypertension
id ES_228e9ecebbd08bbf7558c2f1c9d64555
oai_identifier_str oai:idus.us.es:11441/167505
network_acronym_str ES
network_name_str España
repository_id_str
spelling Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposurePuente, A.Fortea, José IgnacioPozo, C. delSerrano, M.Alonso Peña, M.Giráldez, A.Rodríguez Seguel, Elisa del PilarCrespo, J.OxaliplatinIdiopathic portal hypertensionPorto-sinusoidal vascular disorderPortal hypertensionBackground and aims Oxaliplatin (OX) has been described as a potential etiologic agent for porto-sinusoidal vascular disorder (PSVD). Our aim was to describe the natural history of PSVD due to OX in colon cancer (CRC) and identify risk factors for its development. Methods We made a multicenter retrospective case-control (ratio 1:3) study with patients diagnosed of PSVD-OX. Baseline data, end of treatment, years of follow-up and diagnosis of PSVD were collected and compared to controls (without PSVD). Besides, 16 different SNPs were selected from bibliography and analyzed by genotyping in the case group to identify potential genetic risk factors. Results 41 cases were identified, with a median time to PSVD diagnosis after the end of OX of 34 months. Spleen diameter was the strongest predictor of PSVD during treatment (OR 43.94 (14.48–133.336); p < 0.0001). Additionally, thrombocytopenia (<150 × 10^9) at one year was a significant disease risk marker (OR 9.35; 95% CI: 3.71–23.58; p = 0.001). We could not establish any significant association between the selected SNPs and PSVD diagnosis. Conclusion The increase of spleen diameter is the strongest predictor of PSVD in patients treated with OX for CRC. These patients could be candidates for a specific follow-up of portal hypertension-related complications.Biología Celular2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/167505https://doi.org/10.1016/j.dld.2024.04.010reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésDigestive and Liver Disease, 56 (10), 1721-1729.http://dx.doi.org/10.1016/j.dld.2024.04.010info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1675052026-06-17T12:51:07Z
dc.title.none.fl_str_mv Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure
title Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure
spellingShingle Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure
Puente, A.
Oxaliplatin
Idiopathic portal hypertension
Porto-sinusoidal vascular disorder
Portal hypertension
title_short Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure
title_full Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure
title_fullStr Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure
title_full_unstemmed Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure
title_sort Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure
dc.creator.none.fl_str_mv Puente, A.
Fortea, José Ignacio
Pozo, C. del
Serrano, M.
Alonso Peña, M.
Giráldez, A.
Rodríguez Seguel, Elisa del Pilar
Crespo, J.
author Puente, A.
author_facet Puente, A.
Fortea, José Ignacio
Pozo, C. del
Serrano, M.
Alonso Peña, M.
Giráldez, A.
Rodríguez Seguel, Elisa del Pilar
Crespo, J.
author_role author
author2 Fortea, José Ignacio
Pozo, C. del
Serrano, M.
Alonso Peña, M.
Giráldez, A.
Rodríguez Seguel, Elisa del Pilar
Crespo, J.
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Biología Celular
dc.subject.none.fl_str_mv Oxaliplatin
Idiopathic portal hypertension
Porto-sinusoidal vascular disorder
Portal hypertension
topic Oxaliplatin
Idiopathic portal hypertension
Porto-sinusoidal vascular disorder
Portal hypertension
description Background and aims Oxaliplatin (OX) has been described as a potential etiologic agent for porto-sinusoidal vascular disorder (PSVD). Our aim was to describe the natural history of PSVD due to OX in colon cancer (CRC) and identify risk factors for its development. Methods We made a multicenter retrospective case-control (ratio 1:3) study with patients diagnosed of PSVD-OX. Baseline data, end of treatment, years of follow-up and diagnosis of PSVD were collected and compared to controls (without PSVD). Besides, 16 different SNPs were selected from bibliography and analyzed by genotyping in the case group to identify potential genetic risk factors. Results 41 cases were identified, with a median time to PSVD diagnosis after the end of OX of 34 months. Spleen diameter was the strongest predictor of PSVD during treatment (OR 43.94 (14.48–133.336); p < 0.0001). Additionally, thrombocytopenia (<150 × 10^9) at one year was a significant disease risk marker (OR 9.35; 95% CI: 3.71–23.58; p = 0.001). We could not establish any significant association between the selected SNPs and PSVD diagnosis. Conclusion The increase of spleen diameter is the strongest predictor of PSVD in patients treated with OX for CRC. These patients could be candidates for a specific follow-up of portal hypertension-related complications.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/167505
https://doi.org/10.1016/j.dld.2024.04.010
url https://hdl.handle.net/11441/167505
https://doi.org/10.1016/j.dld.2024.04.010
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Digestive and Liver Disease, 56 (10), 1721-1729.
http://dx.doi.org/10.1016/j.dld.2024.04.010
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404588655771649
score 15.812429

Registros relacionados